Cardiac troponin T vs other biochemical markers in patients with congestive heart failure

Circulation Journal

Volumn 71, Issue 5, 2007, Pages 631-635

  Nishio, Yukiko ^a   Sato, Yukihito ^b   Taniguchi, Ryoji ^b   Shizuta, Satoshi ^a   Doi, Takahiro ^a   Morimoto, Takeshi ^a   Kimura, Takeshi ^a   Kita, Toru ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO PREFECTURAL AMAGASAKI GENERAL MEDICAL CENTER   (Japan)

Author keywords

Brain natriuretic peptide; C reactive protein; Collagen; Heart failure; Norepinephrine; Renin; Troponin

Indexed keywords

BIOCHEMICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CARBOXY TERMINAL TELOPEPTIDE; CHOLESTEROL; COLLAGEN TYPE 1; HEMOGLOBIN; HEMOGLOBIN A1C; NORADRENALIN; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; RENIN; TROPONIN; URIC ACID;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONCENTRATION RESPONSE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; FEMALE; HEART MUSCLE INJURY; HEMOGLOBIN BLOOD LEVEL; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATHOPHYSIOLOGY; PROGNOSIS; PROTEIN BLOOD LEVEL;

AGED; AGING; BIOLOGICAL MARKERS; FEMALE; HEART FAILURE, CONGESTIVE; HOSPITALIZATION; HUMANS; MALE; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; NOREPINEPHRINE; PATIENT READMISSION; PROGNOSIS; RENIN; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; TROPONIN T;

EID: 34247608834     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.71.631     Document Type: Article

References (35)

1. Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348: 2007-2018.
2. McMurray JJV, Pfeffer MA. Heart failure. Lancet 2005; 365: 1877-1889.
3. Cohn JN, Ferrari R, Sharp N. Cardiac remodeling-concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 2000; 35: 569-582.
4. St John Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: Pathophysiology and therapy. Circulation 2000; 101: 2981-2988.
5. Maisel A. Understanding B-type natriuretic peptide and its role in diagnosis and monitoring congestive heart failure. Clin Cornerstone 2005; 7: S7-S17.
6. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311: 819-823.
7. Cohn JN, Johnson GR, Shabetai R, Loeb H, Tristani F, Rector T, et al for the V-HeFT VA Cooperative Studies Group. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. Circulation 1993; 87(Suppl VI): VI-5-VI-16.
8. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A for the V-HeFT VA Cooperative Studies Group. Plasma norepinephrine, plasma renin activity, and congestive heart failure: Relations to survival and the effects of therapy in V-HeFT II. Circulation 1993; 87(Suppl VI): VI-40-VI-48.
9. Deswal A, Peterson NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the Vesnarinone Trail (VEST). Circulation 2001; 103: 2055-2059.
10. Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Masson S, et al. C-reactive protein in heart failure: Prognostic value and the effect of Valsartan. Circulation 2005; 112: 1428-1434.
11. Klappacher G, Franzen P, Haab D, Mehrabi M, Binder M, Plesch K, et al. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol 1995; 75: 913-918.
12. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Circulation 2000; 102: 2700-2706.
13. Sato Y, Kataoka K, Matsumori A, Sasayama S, Yamada T, Ito H, et al. Measuring serum aminoterminal tyeIII procollagen peptide, 7S domain of type IV collagen, and cardiac troponin T in patients with idiopathic dilated cardiomyopathy and secondary cardiomyopathy. Heart 1997; 78: 505-508.
14. Poulsen SH, Host NB, Jensen SE, Egstrup K. Relationship between serum amino-terminal propeptide of type III procollagen and changes of left ventricular function after acute myocardial infarction. Circulation 2000; 101: 1527-1532.
15. Sato Y, Yamada T, Taniguchi R, Nagai K, Makiyama T, Okada H, et al. Persistently increased serum concentrations of cardiac troponin T in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation 2001; 103: 369-374.
16. Sato Y, Kita T, Takatsu Y, Kimura T. Biochemical markers of myocyte injury in heart failure (Review). Heart 2004; 90: 1110-1113.
17. Taniguchi R, Sato Y, Yamada T, Ooba M, Higuchi H, Matsumori A, et al. Combined measurements of cardiac troponin T and N-terminal pro-brain natriuretic peptide in patients with chronic heart failure. Circ J 2004; 68: 1160-1164.
18. Setsuta K, Seino Y, Ogawa T, Ohtsuka T, Seimiya K, Takano T. Ongoing myocardial damage in chronic heart failure is related to activated tumor necrosis factor and Fas/Fas ligand system. Circ J 2004; 68: 747-750.
19. Koh E, Nakamura T, Takahashi H. Troponin-T and brain natriuretic peptide as predictors for adriamycin-induced cardiomyopathy in rats. Circ J 2004; 68: 163-167.
20. Teiger E, Dam T-V, Richard L. Apoptosis in pressure overload-induced heart hypertrophy in the rat. J Clin Invest 1996; 97: 2891-2897.
21. Mann DL, Kent RL, Parsons B, Cooper G. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992; 85: 790-804.
22. Tan LB, Jalil JE, Pick R, Janicki JS, Weber KT. Cardiac myocyte necrosis induced by angiotensin II. Circ Res 1991; 69: 1185-1195.
23. Kajstura J, Cigola E, Malhotra A, Li P, Cheng W, Meggs LG, et al. Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol 1997; 29: 859-870.
24. Krown KA, Page MT, Nguyen C, Zechner D, Gutierrez V, Comstock KL, at al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes: Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 1996; 98: 2854-2865.
25. Bhambi B, Eghbali M. Effect of norepinephrine on myocardial collagen gene expression and response of cardiac fibroblasts after norepinephrine treatment. Am J Pathol 1991; 139: 1131-1142.
26. Crabos M, Roth M, Hahn AW, Erne P. Characterization of angiotensin II receptors in cultured adult rat cardiac fibroblasts: Coupling to signaling systems and gene expression. J Clin Invest 1994; 93: 2372-2378.
27. Benjamin IJ, Jalil JE, Tan LB, Cho K, Weber KT, Clark WA. Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis. Circ Res 1989; 65: 657-670.
28. Anand IS, Kuskowski MA, Rector TS, Florea VG, Glazer RD, Hester A, et al. Anemia and changes in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: Results from Val-HeFT. Circulation 2005; 112: 1121-1127.
29. Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, et al. Uric acid and survival in chronic heart failure: Validation and application in metablic, functional, and hemodynamic staging. Circulation 2003; 107: 1991-1997.
30. Rauchhaus M, Clark AL, Doehner W, Davos C, Bolger A, Sharma R, et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003; 42: 1933-1940.
31. Swan JW, Anker SD, Walton C, Godsland IF, Clark AL, Leyva F, et al. Insulin resistance in chronic heart failure: Relation to severity and etiology of heart failure. J Am Coll Cardiol 1997; 30: 527-532.
32. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: Prognostic and therapeutic implications from a prospective cohort study. Circulation 2004; 109: 1004-1009.
33. Perna ER, Macin SM, Canella JPC, Augier N, Stival JL, Cialzeta JR, et al. Ongoing myocardial injury in stable severe heart failure. Value of cardiac troponin T monitoring for high-risk patient identification. Circulation 2004; 110: 2376-2382.
34. Ishii J, Nomura M, Nakamura Y, Naruse H, Mori Y, Ishikawa T, et al. Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Am J Cardiol 2002; 89: 691-695.
35. Anand IS, Florea VG, Fisher L. Surrogate end points in heart failure. J Am Coll Cardiol 2002; 39: 1414-1421.